Showing 11-20 of 27 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Project Tuyinza | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-April-2026 to 31-March-2029 | $643,550.00 |
| Triple therapy for T1DM with insulin, semaglutide and dapagliflozin | The Research Foundation of SUNY on behalf of University at Buffalo | Paresh Dandona | Improving Lives | 01-January-2019 to 31-December-2026 | $1,808,522.70 |
| GPR75, a novel actor in beta cell regeneration | New York Medical College | Ercument Dirice | Cures | 01-April-2022 to 31-March-2027 | $750,000.00 |
| Market Analysis of Devices Utilized By Patients With T1D & Eligibility For Future T1D Cell and Gene Therapies | Milliman | Rebecca Smith | Cures | 01-January-2025 to 31-October-2025 | $380,000.00 |
| Market Analysis of Insulin Products Utilized by Patients With T1D & Pervasiveness of Insulin Caps | Milliman | Rebecca Smith | Transportfolio | 01-January-2025 to 31-December-2025 | $590,000.00 |
| Autoimmune stem-like T cells in type 1 diabetes | Memorial Sloan-Kettering Cancer Center | Andrea Schietinger | Cures | 01-September-2023 to 31-August-2026 | $750,000.00 |
| Bringing Beta Cell Regenerative Therapy to the Clinic | Icahn School of Medicine at Mount Sinai | Andrew Stewart | Cures | 01-January-2024 to 31-December-2026 | $1,000,000.00 |
| The KQ1 serum study: amendment & extension | Icahn School of Medicine at Mount Sinai | Dirk Homann | Cures | 01-November-2024 to 31-October-2027 | $1,873,290.24 |
| Exploring the Effects of Beta Cell Regenerative Drugs on Cell Fate Decisions in Human Pancreatic Islets | Icahn School of Medicine at Mount Sinai | Esra Karakose | Cures | 01-March-2025 to 28-February-2030 | $999,999.00 |
| Enhancing Functional Maturation of Stem Cell-Derived Beta Cells Using Harmine for Improved Diabetes Therapy | Icahn School of Medicine at Mount Sinai | Peng Wang | Cures | 01-July-2025 to 30-June-2026 | $305,000.00 |